From Name

From Email

To Name

To Email

Message

FDA approves Belantamab Mafodotin-blmf to treat R/R multiple myeloma

from Oncology Nursing News

FDA approves Belantamab Mafodotin-blmf to treat R/R multiple myeloma Oncology Nursing News The FDA has approved belantamab mafodotin-blmf (Blenrep) as a treatment for patients with relapsed/refractory multiple myeloma who have received four prior therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody. READ MORE

more